SCHEMBL3200431

SCHEMBL3200431

CN1CCc2cc(S(=O)(=O)Cl)ccc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.43
GLA P06280 1/20 0.43
MAPT P10636 3/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
ALDH1A1 P00352 1/20 0.43
GAA P10253 1/20 0.43
HPGD P15428 1/20 0.43
NOTUM Q6P988 1/20 0.42
PKM P14618 2/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA7 P43166 1/20 0.40
CA9 Q16790 1/20 0.40
ROCK1 Q13464 1/20 0.39
WDR5 P61964 1/20 0.39
TP53 P04637 3/20 0.39
NPC1 O15118 1/20 0.39
CYP1A2 P05177 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL38660212 1.00 POLB (0.43) POLBGLAMAPTMEN1KMT2A
SCHEMBL3127789 0.90 ALDH1A1 (0.55) POLBGLAMAPTMEN1KMT2A
SCHEMBL3128006 0.87 NOTUM (0.42) POLBGLAMEN1KMT2AALDH1A1
SCHEMBL15739728 0.85 ROCK1 (0.52) POLBGLAMAPTMEN1KMT2A
SCHEMBL3227479 0.85 CA12 (0.47) POLBGLAMAPTMEN1KMT2A
SCHEMBL28457831 0.83 CA1 (0.56) POLBGLAMAPTMEN1KMT2A
SCHEMBL2625803 0.81 HTR2C (0.51) POLBGLAMAPTMEN1KMT2A
SCHEMBL25252571 0.80 GRM5 (0.51) MEN1KMT2A
SCHEMBL3112781 0.80 NOTUM (0.45) POLBGLAMAPTALDH1A1HPGD
SCHEMBL31130019 0.80 NOTUM (0.45) POLBGLAMAPTALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107098846-B N-acyl sulfonamide FBPase inhibitor, preparation method thereof, pharmaceutical composition and application thereof 中国医学科学院药物研究所 2020-10-09 CN disclosed
CN-102942558-B Preparation method of benzazepine derivatives TIANJIN INST PHARM RESEARCH 2014-04-16 CN disclosed
CN-102942558-A Preparation method of benzazepine derivatives TIANJIN INST PHARM RESEARCH 2013-02-27 CN disclosed
EP-2184990-A2 3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY Memory Pharmaceuticals Corporation (US) 2010-05-19 EP disclosed
WO-2010024980-A1 4'-AMINO CYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2010-03-04 WO disclosed
US-20100056491-A1 4'-AMINO CYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2010-03-04 US disclosed
US-20100056531-A1 ALKYL-SUBSTITUTED 3' COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2010-03-04 US disclosed
WO-2010021797-A1 CONDENSED HETEROCYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-25 WO disclosed
US-20090069337-A1 3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2009-03-12 US disclosed
WO-2009023844-A2 3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2009-02-19 WO disclosed
US-20050187246-A1 Cell proliferation inhibitors LI QUN (US) 2005-08-25 US disclosed
US-6924304-B2 Cell proliferation inhibitors ABBOTT LABORATORIES (US) 2005-08-02 US disclosed
US-20030096856-A1 Cell proliferation inhibitors ABBVIE INC. 2003-05-22 US disclosed
US-6521658-B1 Cell proliferation inhibitors ABBOTT LABORATORIES 2003-02-18 US disclosed
EP-1181269-A1 CELL PROLIFERATION INHIBITORS ABBOTT LABORATORIES (US) 2002-02-27 EP disclosed
WO-2000073264-A1 CELL PROLIFERATION INHIBITORS ABBOTT LABORATORIES (US) 2000-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069337-A1 3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY HTR6, HTR3A, HTR3B POLB 4064/4885GLA 4781/4885MAPT 4091/4885
US-20100056531-A1 ALKYL-SUBSTITUTED 3' COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY HTR6, HTR3B, HTR1B POLB 2751/4885GLA 4233/4885MAPT 4418/4885
US-20030096856-A1 Cell proliferation inhibitors MKI67, CCNI, CCNA1 POLB 325/4885GLA 2268/4885MAPT 4317/4885
US-20050187246-A1 Cell proliferation inhibitors MKI67, CCNI, CCNC POLB 237/4885GLA 1902/4885MAPT 4131/4885
US-20100056491-A1 4'-AMINO CYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY HTR6, HTR4, HTR3B POLB 3666/4885GLA 4368/4885MAPT 4436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.